Ceprate SC PMA to be reviewed:
This article was originally published in Clinica
Executive Summary
The US FDA's biological response modifiers advisory committee is due to discuss CellPro's PMA for the Ceprate SC device for selection of CD34+ progenitor/stem cells at its meeting on February 28th. Meanwhile, 134 patients are being enrolled for a Phase III US trial to use the system to deplete tumour cells from peripheral blood stem cell transplants in multiple myeloma treatment.